Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Mon, 29.03.2021
Cardiol Therapeutics
GBC Research Watchlist: Cardiol Therapeutics Inc.
'The right moment to participate in this exciting growth story'
Cortalex - The purest form of CBD, no THC. It matters.
For many patient segments, CBD medication can be linked to the possibility
of becoming intoxicated by THC. For children, young adults under 25,
workers that cannot be intoxic [ … ]
Wed, 27.01.2021
Media and Games Invest plc
26/01/2021 - GBC Management Interview with Paul Echt, CFO of Media and
Games Invest Group
' We clearly want to reach the billion market capitalisation here and
continue to grow beyond that. '
Media and Games Invest (MGI) is a fast and profitable growing digital media
and games company. The company combines organic growth with targeted valuecre [ … ]
Thu, 14.01.2021
The NAGA Group AG
High growth momentum achieved in 2020; guidance for 2021 clearly above our
expectations; price target raised to EUR7.03 (previously: EUR4.30); BUY
rating
As expected, the preliminary figures of The NAGA Group AG (NAGA for short)
for the past financial year 2020 were characterised by very high growth
dynamic. Revenues of EUR25.9 million (PY: EUR6 [ … ]
Mon, 21.12.2020
Coreo AG
Planned financing successfully implemented, high liquidity available for
new investments, target price of EUR 2.35 and BUY rating confirmed
As announced after the cancellation of the bond issue by Coreo AG, the
company has successfully concluded a replacement financing. According to
the latest company announcement, the company has received a loa [ … ]
Fri, 18.12.2020
MagForce AG
Capital increase of EUR4.7m successfully implemented to finance growth
strategy, high share price potential, BUY rating confirmed
Since our last research study (see research study dated 12.11.2020), the
share price of MagForce AG has developed significantly positively. Within
just one month, the share price has risen significantly by approximate [ … ]
Wed, 16.12.2020
MBH Corporation plc
With four further acquisitions, our expectations were exceeded; price
target slightly increased; share clearly undervalued
MBH Corporation plc (MBH for short) has continued to show a high level of
acquisition activity compared to our last research report (see report dated
08.10.2020), as has been the case so far this year. On 30 October, the
com [ … ]
Mon, 07.12.2020
Media and Games Invest plc
9 Months 2020: MGI continues on a clear growth course, expansion of mobile
gaming activities opens up additional high revenue potential; company
guidance raised again; increase of forecasts and target price
On 30 November 2020, Media and Games Invest plc (MGI) announced its Q3
business figures and 9-month business figures respectively. On the ba [ … ]
Mon, 07.12.2020
The NAGA Group AG
Strong sales and earnings growth continued in third quarter; forecasts and
price target increased
With the publication of the preliminary half-year figures for 2020, it was
already known that The NAGA Group AG (NAGA) had achieved the operational
turn-around. After comparatively low sales and a negative earnings level in
the previous year, the no [ … ]
Mon, 30.11.2020
Aves One AG
Growth course continued after nine months; target price and BUY rating
confirmed
As expected, Aves One AG has also achieved sales growth of 9.1% to EUR93.60
million (previous year: EUR85.82 million) after the first nine months of
2020. Even adjusted for extraordinary revenues from the sale of a last
logistics property amounting to EUR 3.39 milli [ … ]
Thu, 12.11.2020
MagForce AG
Significant treatment revenues generated for the first time, roll-out in
Europe and Germany to be continued; Approval for prostate treatment
expected in 2021
In the first six months of 2020, MagForce AG treated a significant number
of glioblastoma patients for the first time. By treating 11 patients in
Germany and six patients in Poland, the com [ … ]